替吉奥胶囊联合奥沙利铂治疗晚期胃癌的疗效分析

目的观察替吉奥(S-1)胶囊联合奥沙利铂治疗晚期胃癌的近期疗效及毒副反应。方法将62例具有可测量病灶的晚期胃癌患者随机分为2组。S-1组(n=30)根据体表面积确定S-1与奥沙利铂的初始剂量;FOLFOX7组(n=32)使用5-氟尿嘧啶(5-Fu)、亚叶酸钙(CF)和奥沙利铂,2组均于2个周期后评估疗效。结果 S-1组完全缓解(CR)1例,部分缓解(PR)12例,有效率为43.3%;FOLFOX7组CR1例,PR 11例,有效率为37.5%,2组有效率比较无统计学意义。2组患者不良反应主要为恶心、呕吐、骨髓抑制、周围神经毒性及肝肾损害,2组不良反应无显著差异。结论 S-1胶囊联合奥沙利铂治疗进展期胃癌与FOLFOX7疗效相当,但不良反应较轻,耐受性较好。

Analysis of therapeutic effects of S-1 capsules combined with oxaliplatin for advanced gastric cancer

Objective To observe the shortA1.term effects and adverse reactions of SA1.1 capsules combined with oxaliplatin for advanced gastric cancer.Methods SixtyA1.two patients with measurable focus and advanced gastric cancer were randomly divided into two groups.The initial dosages of SA1.1 and oxaliplatin were confirmed in SA1.1 group(n=30) according to body surface areas.FOLFOX 7 group(n=32) was applied with 5A1.fluorouracil(5A1.Fu),calcium folinatc(CF) and oxaliplatin.The therapeutic effects of both groups were evaluated after two cycles.Results In SA1.1 group,complete remission(CR) was found in 1 case,partial remission(PR) 12 cases and the effectiveness rate was 43.3%.Whereas in FOLFOX7,CR was found in 1 case,PR 11 cases and the effectiveness rate was 37.5%.There was no statistical significance compared with the effectiveness rates of both groups.The adverse reactions of patients in the two groups mainly included nausea,vomiting,bone marrow suppression,peripheral neurotoxicity,liver and kidney damage,but there was no significant difference between adverse reactions.Conclusion The therapeutic effects of SA1.1 capsules combined with oxaliplatin in the treatment of advanced gastric cancer are similar to FOLFOX7,but its adverse reactions are less and tolerance is better.